SMN1 and proximal spinal muscular atrophy: Our data are consistent with gene therapy trials in patients with spinal muscular atrophy treated with systemic AAV9-SMN1 at 2 x1014 vg/kg that have shown remarkable efficacy with little observed toxicity [5].